Johnson & Johnson Aims To Regain Remicade Rights

Law360, New York (May 21, 2009, 12:00 AM EDT) -- Johnson & Johnson plans to head to arbitration to seek the return of its full rights to market and sell arthritis treatment Remicade from Schering-Plough Corp. now that Merck & Co. plans to acquire the pharmaceutical company.

The merger plan allows Johnson & Johnson to terminate a deal with Schering-Plough that gives the Kenilworth, N.J.-based company the rights to distribute Remicade and related products in markets outside the U.S., Johnson & Johnson said Thursday.

In a regulatory filing with the U.S. Securities and Exchange Commission on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.